NAD+ Decline Drives Aging and Menopause — Can NMN and NR Turn It Around?

As women enter menopause, estrogen depletion triggers a cascade of biological changes that accelerate aging — including mitochondrial dysfunction, oxidative stress, chronic inflammation, and impaired DNA repair. Emerging evidence suggests that declining NAD+ levels sit at the center of this process, making NAD+ metabolism a compelling therapeutic target for both longevity medicine and menopausal health.

This narrative review synthesizes current experimental and clinical evidence linking NAD+ biology to aging and menopause. The authors searched PubMed, Scopus, and Web of Science for studies on NAD+ metabolism, NMN, nicotinamide riboside (NR), mitochondrial dysfunction, inflammatory signaling, and menopause. The review spans mechanistic pathways and available human trial data.

Key findings indicate that intracellular NAD+ depletion during aging disrupts mitochondrial homeostasis, impairs cellular energy production, fuels chronic inflammatory signaling, and may contribute to neurodegeneration. Two enzymes — sirtuins and PARPs — that depend on NAD+ for DNA repair and gene regulation become compromised as NAD+ falls. CD38, an NAD+-consuming enzyme upregulated during chronic inflammation, is identified as a major accelerant of NAD+ depletion in aging and menopause.

NAD+ precursors NMN and NR have demonstrated biological efficacy in animal models and some early human studies, improving mitochondrial function, reducing inflammation markers, and supporting metabolic regulation. However, pharmacokinetic instability, poor tissue-specific bioavailability, and wide variability in clinical responses limit the translation of these findings into firm treatment guidelines.

The authors conclude that while NAD+ modulation represents a scientifically grounded and mechanistically plausible approach to slowing menopausal aging, robust long-term randomized clinical trials are still absent. Until such evidence accumulates, NAD+ precursor supplementation should be considered investigational rather than standard of care for menopausal women.